Multiple RTKs can be co-expressed in resistant melanoma cells, with expression clusters involving EGFR, ERBB3, AXL and PDGFR being identified [37,121,122] leading to multiple resistance drivers that are difficult to target with single drugs. This evidence concerns the gene ERBB3 and melanoma.